SMMT Stock | | | USD 21.41 0.31 1.47% |
Summit Therapeutics financial indicator trend analysis is much more than just breaking down Summit Therapeutics PLC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Summit Therapeutics PLC is a good investment. Please check the relationship between Summit Therapeutics Common Stock Total Equity and its Accounts Payable accounts. Check out
World Market Map to better understand how to build diversified portfolios, which includes a position in Summit Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in population.
Common Stock Total Equity vs Accounts Payable
Common Stock Total Equity vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Summit Therapeutics PLC Common Stock Total Equity account and
Accounts Payable. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Summit Therapeutics' Common Stock Total Equity and Accounts Payable is -0.25. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Summit Therapeutics PLC, assuming nothing else is changed. The correlation between historical values of Summit Therapeutics' Common Stock Total Equity and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Summit Therapeutics PLC are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Common Stock Total Equity i.e., Summit Therapeutics' Common Stock Total Equity and Accounts Payable go up and down completely randomly.
Correlation Coefficient | -0.25 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.
Accounts Payable
An accounting item on the balance sheet that represents Summit Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Summit Therapeutics PLC are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Summit Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Summit Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
World Market Map to better understand how to build diversified portfolios, which includes a position in Summit Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in population.
At this time, Summit Therapeutics'
Selling General Administrative is comparatively stable compared to the past year.
Sales General And Administrative To Revenue is likely to gain to 35.83 in 2024, whereas
Enterprise Value Over EBITDA is likely to drop
(19.78) in 2024.
Summit Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Summit Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Summit Therapeutics fundamental ratios Accounts
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to
measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.